30/10/2026
𝐅𝐮𝐧 𝐅𝐚𝐜𝐭 𝐅𝐫𝐢𝐝𝐚𝐲! 💊
𝐃𝐞𝐮𝐜𝐫𝐚𝐯𝐚𝐜𝐢𝐭𝐢𝐧𝐢𝐛 is an oral medication used to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It selectively inhibits tyrosine kinase 2 (TYK2), a protein involved in inflammatory signaling pathways regulated by interleukin-12 (IL-12), interleukin-23 (IL-23), and type I interferons. By suppressing these pathways, deucravacitinib helps reduce skin inflammation and psoriasis symptoms.
Its once-daily oral administration offers a convenient treatment option. Compared with apremilast and other systemic treatments, its efficacy and safety profile have been evaluated in clinical studies, although individual outcomes may vary.
𝐌𝐞𝐜𝐡𝐚𝐧𝐢𝐬𝐦 𝐨𝐟 𝐀𝐜𝐭𝐢𝐨𝐧
Deucravacitinib selectively inhibits tyrosine kinase 2 (TYK2), an enzyme in the Janus kinase (JAK) family responsible for activating the JAK–STAT signaling pathway. TYK2 regulates inflammatory responses mediated by interleukin-12 (IL-12), interleukin-23 (IL-23), and type I interferons. In psoriasis, IL-23 stimulates T-helper 17 (Th17) cells to produce inflammatory mediators, including IL-17 and tumor necrosis factor-alpha (TNF-α), which contribute to skin inflammation and excessive epidermal cell growth.
Deucravacitinib binds allosterically to the regulatory pseudokinase (JH2) domain of TYK2, inducing a conformational change that keeps the enzyme inactive. In laboratory studies, it demonstrated approximately 100- to 2,000-fold greater selectivity for TYK2 than for JAK1, JAK2, and JAK3, with minimal binding to these other enzymes. This selective inhibition reduces inflammatory signaling and the expression of psoriasis-associated genes, including those involved in the IL-23 and type I interferon pathways.
After 16 weeks of once-daily treatment, reductions in inflammatory markers such as IL-17A, IL-19, and beta-defensin were observed in patients with psoriasis. However, the precise relationship between these molecular changes and the drug's clinical effects remains incompletely understood.
𝐂𝐨𝐦𝐦𝐨𝐧 𝐒𝐢𝐝𝐞 𝐄𝐟𝐟𝐞𝐜𝐭𝐬 💊
Deucravacitinib may cause several unwanted effects, including headache, fever, chills, cough, sore throat, sneezing, nasal congestion, and a runny nose. Other possible symptoms include muscle aches, body pain, fatigue, swollen glands, voice changes, and discomfort around the eyes and cheekbones.
These effects may vary among individuals and may be associated with infections, such as upper respiratory tract infections. Patients should monitor their symptoms and consult a healthcare professional if they persist or worsen. Chest tightness, difficulty breathing, or trouble swallowing require immediate medical attention, as these may indicate a serious reaction.
𝗣𝗿𝗲𝗰𝗮𝘂𝘁𝗶𝗼𝗻𝘀 ⚠
Patients taking deucravacitinib should attend regular medical checkups and undergo recommended blood tests to monitor their progress and detect potential adverse effects. Because the medication affects immune signaling, patients should promptly report signs of infection, including fever, chills, cough, or unusual fatigue. Tuberculosis screening is required before treatment, and symptoms of herpes infections, severe allergic reactions, or unusual swelling should be evaluated immediately.
Patients should also seek medical attention for warning signs such as unexplained weight loss, swollen glands, dark urine, severe muscle pain, chest pain, or difficulty breathing. Before receiving any vaccine, patients should consult their doctor and avoid live vaccines during treatment.
𝐓𝐚𝐤𝐞 𝐍𝐨𝐭𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐔𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐞𝐮𝐜𝐫𝐚𝐯𝐚𝐜𝐢𝐭𝐢𝐧𝐢𝐛‼️
Before using deucravacitinib, patients should inform their doctor of any known allergies to medications or substances such as foods, dyes, and preservatives to help prevent possible allergic reactions. The safety and effectiveness of the medication in children have not been established due to limited research. In older adults, deucravacitinib may be used with caution, as they may be more susceptible to serious infections and require closer monitoring.
For breastfeeding mothers, insufficient evidence is available regarding the medication’s safety for infants; therefore, consultation with a healthcare professional is necessary to weigh the potential benefits of treatment against the possible risks.
𝗥𝗘𝗙𝗘𝗥𝗘𝗡𝗖𝗘𝗦
DrugBank. (n.d.). Deucravacitinib: Uses, interactions, mechanism of action. https://go.drugbank.com/drugs/DB16650
Hoy, S. M. (2022). Deucravacitinib: First approval. Drugs, 82(17), 1671–1679. https://doi.org/10.1007/s40265-022-01796-y
Kalola, U. K., Alberty, A., & Sheehy, C. (2024). Deucravacitinib. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK606109/
Mayo Clinic. (2026, August 1). Deucravacitinib (oral route). https://www.mayoclinic.org/drugs-supplements/deucravacitinib-oral-route/description/drg-20538853
The Every Day Pill for Everyday Life - SOTYKTU® (deucravacitinib). (n.d.). https://www.sotyktu.com/
XPRT is one of the leading analytical laboratory services companies that provide advanced testing and analytical services to a wide range of healthcare industries, such as drug manufacturers, distributors, importers, hospitals, and drug stores. We also cater these services to cosmetic, veterinary, and other industries alike.
If you need more information about our services or if you have any inquiries, you may reach out to us via email at [email protected] or contact us at (02) 8551-3422 loc. 132.